<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896346</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002861</org_study_id>
    <nct_id>NCT04896346</nct_id>
  </id_info>
  <brief_title>Scarring in Stratagraft-treated vs. Autograft-treated Burn Wounds: a Clinical and Histological Investigation</brief_title>
  <official_title>Scarring in Stratagraft-treated vs. Autograft-treated Burn Wounds: a Clinical and Histological Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Shupp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe and better understand the scars of subjects that&#xD;
      have been treated with Stratagraft tissue vs autograft.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will recruit patients who have previously been participants in the STRATA2016&#xD;
      study protocol. The patients will have comprehensive scar examinations conducted including&#xD;
      the use of imaging, scar scale scores, pain and itch scales, scar volume measurements, and&#xD;
      non-invasive skin measurements resulting in quantitative metrics of skin elasticity,&#xD;
      stiffness, and color. Tissue biopsies will also be collected for histologic investigations&#xD;
      into the scar. Each patient will have a biopsy taken of the autografted site, the Stratagraft&#xD;
      site, and an area of normal, un-injured skin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize post-burn scar resulting from Stratagraft-treated and autograft-treated wounds</measure>
    <time_frame>1 DAY</time_frame>
    <description>Vancouver Scar Scale scores will be compared between scars originating from Stratagraft-treated burn wounds vs. autograft-treated burn wounds. The data will be normalized to uninjured skin.&#xD;
Min value for this scale is 0 and maximum value is 13. The higher the score, the worse the scar/outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize post-burn scar resulting from Stratagraft-treated and autograft-treated wounds</measure>
    <time_frame>1 DAY</time_frame>
    <description>Patient and Observer Scar Assessment Scale (POSAS) scores will be compared between scars originating from Stratagraft-treated burn wounds vs. autograft-treated burn wounds. The data will be normalized to uninjured skin.&#xD;
Min value for this scale for the patient and observer components are 14 and maximum value is 140. The higher the score, the worse the scar/outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize post-burn scar resulting from Stratagraft-treated and autograft-treated wounds</measure>
    <time_frame>1 DAY</time_frame>
    <description>Pain visual analogue scale scores will be compared between scars originating from Stratagraft-treated burn wounds vs. autograft-treated burn wounds. The data will be normalized to uninjured skin.&#xD;
The lowest value for this scale is 0 and the highest is 100. The higher the value to worse the outcome of pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize post-burn scar resulting from Stratagraft-treated and autograft-treated wounds</measure>
    <time_frame>1 DAY</time_frame>
    <description>Itch visual analogue scale scores will be compared between scars originating from Stratagraft-treated burn wounds vs. autograft-treated burn wounds. The data will be normalized to uninjured skin.&#xD;
The lowest value for this scale is 0 and the highest is 100. The higher the value to worse the outcome of itch.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize post-burn scar resulting from Stratagraft-treated and autograft-treated wounds</measure>
    <time_frame>1 DAY</time_frame>
    <description>Non-invasive skin probe measuring color will be compared between scars originating from Stratagraft-treated burn wounds vs. autograft-treated burn wounds. The data will be normalized to uninjured skin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize post-burn scar resulting from Stratagraft-treated and autograft-treated wounds</measure>
    <time_frame>1 DAY</time_frame>
    <description>Non-invasive skin probe measuring elasticity will be compared between scars originating from Stratagraft-treated burn wounds vs. autograft-treated burn wounds. The data will be normalized to uninjured skin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize post-burn scar resulting from Stratagraft-treated and autograft-treated wounds</measure>
    <time_frame>1 DAY</time_frame>
    <description>Non-invasive skin probe measuring stiffness will be compared between scars originating from Stratagraft-treated burn wounds vs. autograft-treated burn wounds. The data will be normalized to uninjured skin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize post-burn scar resulting from Stratagraft-treated and autograft-treated wounds</measure>
    <time_frame>1 DAY</time_frame>
    <description>Histologic measurements will be compared between scars originating from Stratagraft-treated burn wounds vs. autograft-treated burn wounds. The data will be normalized to uninjured skin.&#xD;
The specific parameters being measured include epidermal thickness (microns), dermal thickness (microns), scar cellularity (percentages), and rete ridge ratios (ratio of basement membrane length over epidermis length).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualitatively characterize scar resulting from Stratagraft-treated and autograft-treated wounds</measure>
    <time_frame>1 DAY</time_frame>
    <description>Digital images and 3D photography will be used to qualitatively characterize scars.&#xD;
Formalin-fixed, paraffin embedded (FFPE) samples will be used to generate sections which will be stained with Massons trichrome (overall collagen), Pircosirius red (type I and III collagen), Verhoeff Van Geison (elastin), and Fontana Masson (melanin) stains. These stained sections will be imaged and used to qualitatively characterize scar resulting from Stratagraft-treated burn wounds and SOC-treated burn wounds. Images will be normalized to uninjured skin.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Burn Scar</condition>
  <condition>Scar</condition>
  <arm_group>
    <arm_group_label>Previous Treatment: Biologic StrataGraft Skin Tissue</arm_group_label>
    <description>This consists of areas that were treated with Stratagraft Skin Tissue under a previous clinical study STRATA2016.&#xD;
No new interventions will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previous Treatment: Autograft Comparator</arm_group_label>
    <description>This consists of areas that were treated with autograft comparator under a previous clinical study STRATA2016.&#xD;
No new interventions will occur.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Punch biopsy</intervention_name>
    <description>punch biopsies will be used for histologic analysis and biochemical assays</description>
    <arm_group_label>Previous Treatment: Autograft Comparator</arm_group_label>
    <arm_group_label>Previous Treatment: Biologic StrataGraft Skin Tissue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-invasive photography, assessments, and measurements</intervention_name>
    <description>photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity</description>
    <arm_group_label>Previous Treatment: Autograft Comparator</arm_group_label>
    <arm_group_label>Previous Treatment: Biologic StrataGraft Skin Tissue</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      One 3-millimeter punch biopsy will be obtained from each subjects Stratagraft Treated Site,&#xD;
      Autograft Comparator Site, and Normal Skin.&#xD;
&#xD;
      Blood will be collected using EDTA, SST, PAXgene RNA and PAXgene DNA tubes for future&#xD;
      analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited using the participant enrollment records from the STRATA2016&#xD;
        that took place at MedStar Washington Hospital Center/MedStar Health Research Institute.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Participant in STRATA2016 clinical trial&#xD;
&#xD;
          2. â‰¥ 18 years of age&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Unable to provide informed consent&#xD;
&#xD;
          2. Known allergy to lidocaine&#xD;
&#xD;
          3. Scars are not appropriate for investigation based on clinical judgement by the&#xD;
             Principal Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah E Burkey</last_name>
    <phone>202-877-0344</phone>
    <email>sarah.e.burkey@medstar.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medstar Health Research Institute</investigator_affiliation>
    <investigator_full_name>Jeffrey Shupp</investigator_full_name>
    <investigator_title>Director, Burn Center</investigator_title>
  </responsible_party>
  <keyword>stratagraft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

